Genome editing in the spotlight: genetic disorder carriers' views shape the conversation

In a recent article published in Natures Humanities and Social Sciences Communications Journal, researchers performed a qualitative study in the Netherlands to explore value-laden perspectives of the carriers of an autosomal dominant genetic disorder on the applications of somatic genome editing (SGE) and human genome editing (HGE).

In this way, they contributed to the global dialogue on the acceptability of HGE in line with previous public consultations, e.g., the Dutch DNA dialogue.

Study: Between desire and fear: a qualitative interview study exploring the perspectives of carriers of a genetic condition on human genome editing. Image Credit: Natali _ Mis/Shutterstock.comStudy: Between desire and fear: a qualitative interview study exploring the perspectives of carriers of a genetic condition on human genome editing. Image Credit: Natali _ Mis/Shutterstock.com

Background

Many previous studies have presented the views of different stakeholders, e.g., experienced genetic professionals, people not affected by any genetic disorder, and those with a genetic disorder, on the future implementation of HGE. However, they often underestimate the quality of life of those affected by such diseases.

Also, as scientists alone cannot address moral and societal questions concerning HGE, it is vital to consider the 'worldviews,' i.e., the human ability to reflect on existential questions beyond religious and secular (non-religious) frameworks, of people affected by genetic disorders when using HGE.

HGE, i.e., initiating a pregnancy with a modified embryo to pass on altered genes to a potential child, is currently prohibited in many countries, including the Netherlands.

However, the Netherlands allows scientific research involving germline genome editing (GGE) using 'surplus embryos'. These are not intentionally created for research but taken from people receiving fertility treatment who consent to its use for scientific (HGE) research once the treatment is over.

About the study

In the present study, researchers first sent a link to a documentary on the basics of CRISPR-Cas9 technology to the recruited participants, 10 Dutch carriers of an inherited autosomal dominant disorder.

Then, they performed 50-80 minutes semi-structured interviews between April and June 2019 to explore their views on HGE and SGE.  

All the recruited participants were prone to developing a serious genetic condition in the future and carried a 50% chance of passing disease genes to their (potential) offspring.

The team analyzed the gathered data using reflexive thematic analysis on interview transcripts to familiarize with the data, generate codes, find categories, review, define, and name the themes, and write the report. 

Results

The researchers found one overarching theme and three main themes. Regarding the first theme, i.e., the benefits of SGE and HGE for individuals, the lived experiences of the carriers varied widely.

Regarding the safe use of SGE, participants were positive irrespective of disease severity as long as it was medically safe and effective; likewise, most participants were positive towards HGE use but only for severe genetic conditions. 

SGE treatments involve painful medical procedures and prolonged hospitalizations. Thus, in a previous study among high-risk couples, they preferred HGE themselves than burden their child with the SGE treatment.

However, in this study, the participants had less information about SGE; thus, they had relatively positive views of SGE. It highlights the importance of providing adequate factual information about the technology to help participants take a balanced approach toward different clinical applications of genome editing.

Interestingly, two participants found HGE against their religious beliefs; they found tempering an embryo similar to tempering with God's work. On the contrary, other participants with a religious worldview saw HGE as a gift from God to alleviate suffering, despite the high value they placed on an embryo.

Surprisingly, others viewed HGE as a tool for seeking perfection and apprehended its widespread use.

Currently, HGE use is limited to research and treatment/prevention of severe genetic disorders. The future consequences of HGE use could be strikingly different if it includes enhancement and treatment of relatively less serious conditions.

The study results also raised the issue of contextual factors, such as difficulty in demarcating whether a condition is serious because of its type and expression or an affected person's coping ability. 

In addition, the authors pointed towards country-specific contextual factors, e.g., access to or quality of healthcare in a country and its effect on a person's 'worldviews.'

So, in South Africa, participants willingly agreed to use HGE for immunity against the human immunodeficiency virus (HIV) because of its enormous financial burden and threat of passing on HIV to future generations, whereas, in the Netherlands, participants had opposing views because of the availability of better HIV prevention and treatment opportunities.

Conclusions

Together, the study results pointed towards a complex relationship between how participants perceived the status of an embryo and their views on its use for HGE research. Those with a religious worldview considered the embryo as a person from conception. Yet, some favored using them for HGE research based on the moral worth of an embryo vs. the value of promoting the health of future generations.

Nonetheless, the authors recommended embracing (not resolving) the ambivalent views of the carriers of autosomal dominant genetic conditions, especially when engaging broadly with the public and stakeholders.

Journal reference:
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, August 08). Genome editing in the spotlight: genetic disorder carriers' views shape the conversation. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/news/20230808/Genome-editing-in-the-spotlight-genetic-disorder-carriers-views-shape-the-conversation.aspx.

  • MLA

    Mathur, Neha. "Genome editing in the spotlight: genetic disorder carriers' views shape the conversation". News-Medical. 22 December 2024. <https://www.news-medical.net/news/20230808/Genome-editing-in-the-spotlight-genetic-disorder-carriers-views-shape-the-conversation.aspx>.

  • Chicago

    Mathur, Neha. "Genome editing in the spotlight: genetic disorder carriers' views shape the conversation". News-Medical. https://www.news-medical.net/news/20230808/Genome-editing-in-the-spotlight-genetic-disorder-carriers-views-shape-the-conversation.aspx. (accessed December 22, 2024).

  • Harvard

    Mathur, Neha. 2023. Genome editing in the spotlight: genetic disorder carriers' views shape the conversation. News-Medical, viewed 22 December 2024, https://www.news-medical.net/news/20230808/Genome-editing-in-the-spotlight-genetic-disorder-carriers-views-shape-the-conversation.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists uncover genetic code driving tumor formation and spread